pharmaphorum18h
The rise and market race of anti-IL23p19 therapies in IBD: How ECCO 2025 readouts will shape the anti-interleukin landscape
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
MedPage Today2d
Some Psoriasis Biologics Better Than Others for Preventing Progression to PsA
Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...